JP2012531460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012531460A5 JP2012531460A5 JP2012518113A JP2012518113A JP2012531460A5 JP 2012531460 A5 JP2012531460 A5 JP 2012531460A5 JP 2012518113 A JP2012518113 A JP 2012518113A JP 2012518113 A JP2012518113 A JP 2012518113A JP 2012531460 A5 JP2012531460 A5 JP 2012531460A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- hydroxy
- propionamide
- benzenesulfonylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 4-Benzyloxybenzenesulfonyl Chemical group 0.000 claims 32
- 125000003710 aryl alkyl group Chemical group 0.000 claims 32
- 150000001875 compounds Chemical class 0.000 claims 31
- 150000003839 salts Chemical class 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 16
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 125000000547 substituted alkyl group Chemical group 0.000 claims 13
- 239000002253 acid Substances 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 10
- 125000003107 substituted aryl group Chemical group 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 6
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical group [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 2
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 claims 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- 101000777461 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 17 Proteins 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 2
- 206010037779 Radiculopathy Diseases 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims 2
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 claims 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims 2
- 230000006433 tumor necrosis factor production Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims 1
- UWCNFKCKFSEPKW-PMERELPUSA-N (2s)-2-[4-[(4-fluorophenyl)methyl]piperazin-1-yl]-n-hydroxy-3-[[4-[(2-methylquinolin-4-yl)methoxy]phenyl]sulfonylamino]propanamide Chemical compound C1CN([C@@H](CNS(=O)(=O)C2=CC=C(C=C2)OCC=2C=C(N=C3C=CC=CC3=2)C)C(=O)NO)CCN1CC1=CC=C(F)C=C1 UWCNFKCKFSEPKW-PMERELPUSA-N 0.000 claims 1
- NDILBIRPFZRQSV-KRWDZBQOSA-N (2s)-3-[(4-but-2-ynoxyphenyl)sulfonylamino]-n-hydroxy-2-(4-methylsulfonylpiperazin-1-yl)propanamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)NC[C@@H](C(=O)NO)N1CCN(S(C)(=O)=O)CC1 NDILBIRPFZRQSV-KRWDZBQOSA-N 0.000 claims 1
- GBGOCBVSFWOTED-FQEVSTJZSA-N (2s)-3-[[4-[(3,5-dimethylphenyl)methoxy]phenyl]sulfonylamino]-n-hydroxy-2-imidazolidin-1-ylpropanamide Chemical compound CC1=CC(C)=CC(COC=2C=CC(=CC=2)S(=O)(=O)NC[C@H](N2CNCC2)C(=O)NO)=C1 GBGOCBVSFWOTED-FQEVSTJZSA-N 0.000 claims 1
- OIUKNLHRLRYZSP-NRFANRHFSA-N (2s)-3-[[4-[(3-cyanophenyl)methoxy]phenyl]sulfonylamino]-n-hydroxy-2-(4-methylsulfonylpiperazin-1-yl)propanamide Chemical compound C1CN(S(=O)(=O)C)CCN1[C@H](C(=O)NO)CNS(=O)(=O)C(C=C1)=CC=C1OCC1=CC=CC(C#N)=C1 OIUKNLHRLRYZSP-NRFANRHFSA-N 0.000 claims 1
- FRTIGTXSRUVYBM-NRFANRHFSA-N (2s)-3-[[4-[(4-cyanophenyl)methoxy]phenyl]sulfonylamino]-n-hydroxy-2-(4-methylsulfonylpiperazin-1-yl)propanamide Chemical compound C1CN(S(=O)(=O)C)CCN1[C@H](C(=O)NO)CNS(=O)(=O)C(C=C1)=CC=C1OCC1=CC=C(C#N)C=C1 FRTIGTXSRUVYBM-NRFANRHFSA-N 0.000 claims 1
- DFWYIPDYNWZWMV-FQEVSTJZSA-N (2s)-n-hydroxy-2-(4-methylsulfonylpiperazin-1-yl)-3-[(4-phenylmethoxyphenyl)sulfonylamino]propanamide Chemical compound C1CN(S(=O)(=O)C)CCN1[C@H](C(=O)NO)CNS(=O)(=O)C(C=C1)=CC=C1OCC1=CC=CC=C1 DFWYIPDYNWZWMV-FQEVSTJZSA-N 0.000 claims 1
- NITVPFGZLZEXAL-QHCPKHFHSA-N (2s)-n-hydroxy-3-[[4-[(2-methylquinolin-4-yl)methoxy]phenyl]sulfonylamino]-2-piperazin-1-ylpropanamide Chemical compound N1([C@@H](CNS(=O)(=O)C2=CC=C(C=C2)OCC=2C=C(N=C3C=CC=CC3=2)C)C(=O)NO)CCNCC1 NITVPFGZLZEXAL-QHCPKHFHSA-N 0.000 claims 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 claims 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims 1
- OJPDDQSCZGTACX-UHFFFAOYSA-N 2-[n-(2-hydroxyethyl)anilino]ethanol Chemical compound OCCN(CCO)C1=CC=CC=C1 OJPDDQSCZGTACX-UHFFFAOYSA-N 0.000 claims 1
- LVXSNFPFOJZOFN-UHFFFAOYSA-N 3-[(4-but-2-ynoxyphenyl)sulfonylmethylamino]-n-hydroxy-2-(4-methylsulfonylpiperazin-1-yl)propanamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)CNCC(C(=O)NO)N1CCN(S(C)(=O)=O)CC1 LVXSNFPFOJZOFN-UHFFFAOYSA-N 0.000 claims 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000000439 4-methylpentoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 claims 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010062207 Mycobacterial infection Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000012287 Prolapse Diseases 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims 1
- 208000010476 Respiratory Paralysis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000029033 Spinal Cord disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 102100030416 Stromelysin-1 Human genes 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000035362 autoimmune disorder of the nervous system Diseases 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- WYQFYOPMZXRDFX-PMERELPUSA-N benzyl 4-[(2s)-1-(hydroxyamino)-3-[[4-[(2-methylquinolin-4-yl)methoxy]phenyl]sulfonylamino]-1-oxopropan-2-yl]piperazine-1-carboxylate Chemical compound C1CN([C@@H](CNS(=O)(=O)C2=CC=C(C=C2)OCC=2C=C(N=C3C=CC=CC3=2)C)C(=O)NO)CCN1C(=O)OCC1=CC=CC=C1 WYQFYOPMZXRDFX-PMERELPUSA-N 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims 1
- 239000000920 calcium hydroxide Substances 0.000 claims 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 208000010353 central nervous system vasculitis Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 229930016911 cinnamic acid Natural products 0.000 claims 1
- 235000013985 cinnamic acid Nutrition 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims 1
- 229940043279 diisopropylamine Drugs 0.000 claims 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000000004 hemodynamic effect Effects 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 229960002510 mandelic acid Drugs 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims 1
- 210000004126 nerve fiber Anatomy 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 229910017604 nitric acid Inorganic materials 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 229960003104 ornithine Drugs 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 235000006408 oxalic acid Nutrition 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 208000006473 polyradiculopathy Diseases 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 229940107700 pyruvic acid Drugs 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0954460A FR2947268B1 (fr) | 2009-06-30 | 2009-06-30 | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| FR0954460 | 2009-06-30 | ||
| PCT/FR2010/051331 WO2011001089A1 (fr) | 2009-06-30 | 2010-06-28 | Nouveaux composés benzène-sulfonamides, leur procédé de synthèse et leur utilisation en médecine ainsi qu'en cosmétique |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014170214A Division JP2014224152A (ja) | 2009-06-30 | 2014-08-25 | 新規なベンゼンスルホンアミド化合物、その合成方法、ならびに医薬および化粧品におけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012531460A JP2012531460A (ja) | 2012-12-10 |
| JP2012531460A5 true JP2012531460A5 (enExample) | 2013-08-22 |
| JP5607154B2 JP5607154B2 (ja) | 2014-10-15 |
Family
ID=41600633
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012518113A Expired - Fee Related JP5607154B2 (ja) | 2009-06-30 | 2010-06-28 | 新規なベンゼンスルホンアミド化合物、その合成方法、ならびに医薬および化粧品におけるその使用 |
| JP2014170214A Pending JP2014224152A (ja) | 2009-06-30 | 2014-08-25 | 新規なベンゼンスルホンアミド化合物、その合成方法、ならびに医薬および化粧品におけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014170214A Pending JP2014224152A (ja) | 2009-06-30 | 2014-08-25 | 新規なベンゼンスルホンアミド化合物、その合成方法、ならびに医薬および化粧品におけるその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US8420632B2 (enExample) |
| EP (2) | EP2801568A1 (enExample) |
| JP (2) | JP5607154B2 (enExample) |
| KR (2) | KR101513783B1 (enExample) |
| CN (1) | CN102471260B (enExample) |
| AU (1) | AU2010267872C1 (enExample) |
| CA (1) | CA2764193C (enExample) |
| CY (1) | CY1115734T1 (enExample) |
| DK (1) | DK2448920T3 (enExample) |
| ES (1) | ES2501640T3 (enExample) |
| FR (1) | FR2947268B1 (enExample) |
| HK (1) | HK1206006A1 (enExample) |
| HR (1) | HRP20140881T1 (enExample) |
| IN (1) | IN2011KN05169A (enExample) |
| MX (1) | MX2011013130A (enExample) |
| PL (1) | PL2448920T3 (enExample) |
| PT (1) | PT2448920E (enExample) |
| RU (2) | RU2528826C2 (enExample) |
| SI (1) | SI2448920T1 (enExample) |
| SM (1) | SMT201400168B (enExample) |
| WO (1) | WO2011001089A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2947268B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| FR2950057B1 (fr) * | 2009-09-17 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
| US9586832B2 (en) * | 2013-03-15 | 2017-03-07 | Dru L. DeLaet | Method for destruction of halons |
| US20140275108A1 (en) * | 2013-03-15 | 2014-09-18 | Galderma Research & Development | Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
| CN103224476A (zh) * | 2013-05-25 | 2013-07-31 | 上高县瑞雅精细化工有限公司 | 二乙醇胺法制备1-[2-(2-羟基乙氧基)乙基]哌嗪新工艺 |
| FR3030521B1 (fr) * | 2014-12-23 | 2019-07-26 | Galderma Research & Development | Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique |
| ES2695533T3 (es) | 2016-02-01 | 2019-01-08 | Galderma Res & Dev | Compuestos de bencenosulfonamida, método para su síntesis y uso de los mismos en medicina y cosméticos |
| US12023310B2 (en) * | 2022-08-30 | 2024-07-02 | Gongwin Biopharm Co., Ltd | Method for treating peripheral nerve sheath tumor |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506242A (en) | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
| BR9611479B1 (pt) | 1995-11-13 | 2009-01-13 | Ácidos alfa-iminoidroxÂmicos e carboxÍlicos n-substituÍdos cÍclicos e heterocÍclicos. | |
| TW453995B (en) | 1995-12-15 | 2001-09-11 | Novartis Ag | Certain alpha-substituted arylsulfonamido acetohydroxamic acids |
| TW448172B (en) * | 1996-03-08 | 2001-08-01 | Pharmacia & Upjohn Co Llc | Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation |
| DE69718038D1 (de) | 1996-10-16 | 2003-01-30 | American Cyanamid Co | Herstellung und verwendung von ortho-sulfonamido-heteroarylhydroxamsäuren als matrix-metalloproteinase und tace inhibitoren |
| BR9712524A (pt) | 1996-10-16 | 1999-10-19 | American Cyanamid Co | Acidos beta-sulfonamido-hidroxmicos como inibidores de tace e de metaloproteinase de matriz |
| PT938471E (pt) | 1996-10-16 | 2002-05-31 | American Cyanamid Co | A preparacao e uso de acidos ortosulfonamidoarilhidroxamicos como inibidores de metaloproteinases de matriz e "tace" |
| AU743901B2 (en) | 1996-10-16 | 2002-02-07 | Wyeth Holdings Corporation | Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors |
| ATE223909T1 (de) | 1997-01-23 | 2002-09-15 | Hoffmann La Roche | Sulfamide-metalloprotease inhibitoren |
| NZ506184A (en) * | 1998-02-19 | 2003-05-30 | American Cyanamid Co | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulphanyl, sulphinyl or sulphonyl)-3-substituted-alkyl, aryl or heteroarylamides useful as matrix metalloproteinase inhibitors |
| JP3092798B2 (ja) * | 1998-06-30 | 2000-09-25 | 日本電気株式会社 | 適応送受信装置 |
| CA2355902A1 (en) | 1998-12-22 | 2000-06-29 | F. Hoffmann-La Roche Ag | Sulfonamide hydroxamates |
| US6326516B1 (en) * | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
| AR035478A1 (es) * | 1999-01-27 | 2004-06-02 | Wyeth Corp | Acido amida-hidroxamico, acido acetilenico, beta-sulfonamido y fosfinico como inhibidores de la tace, uso de los mismos para la manufactura de un medicamento y composicion farmaceutica que los contiene |
| AR035313A1 (es) | 1999-01-27 | 2004-05-12 | Wyeth Corp | Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos. |
| EP1431285B1 (en) | 2001-09-07 | 2009-01-07 | Kaken Pharmaceutical Co., Ltd. | Reverse hydroxamic acid derivatives |
| CN1610661A (zh) * | 2001-11-01 | 2005-04-27 | 惠氏控股公司 | 用作基质金属蛋白酶和tace的抑制剂的丙二烯芳基磺酰胺异羟肟酸 |
| TW200616612A (en) * | 2004-10-08 | 2006-06-01 | Wyeth Corp | Method for the teatment of polycystic kidney disease field of invention |
| WO2008045671A1 (en) * | 2006-10-06 | 2008-04-17 | Janssen Pharmaceutica, N.V. | Matrix metalloprotease inhibitors |
| FR2947268B1 (fr) * | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
-
2009
- 2009-06-30 FR FR0954460A patent/FR2947268B1/fr not_active Expired - Fee Related
-
2010
- 2010-06-28 MX MX2011013130A patent/MX2011013130A/es active IP Right Grant
- 2010-06-28 CN CN201080029354.9A patent/CN102471260B/zh not_active Expired - Fee Related
- 2010-06-28 KR KR1020127002265A patent/KR101513783B1/ko not_active Expired - Fee Related
- 2010-06-28 AU AU2010267872A patent/AU2010267872C1/en not_active Ceased
- 2010-06-28 ES ES10745348.2T patent/ES2501640T3/es active Active
- 2010-06-28 IN IN5169KON2011 patent/IN2011KN05169A/en unknown
- 2010-06-28 CA CA2764193A patent/CA2764193C/en not_active Expired - Fee Related
- 2010-06-28 JP JP2012518113A patent/JP5607154B2/ja not_active Expired - Fee Related
- 2010-06-28 EP EP14179708.4A patent/EP2801568A1/fr not_active Withdrawn
- 2010-06-28 RU RU2012102925/04A patent/RU2528826C2/ru not_active IP Right Cessation
- 2010-06-28 WO PCT/FR2010/051331 patent/WO2011001089A1/fr not_active Ceased
- 2010-06-28 SI SI201030737T patent/SI2448920T1/sl unknown
- 2010-06-28 HR HRP20140881AT patent/HRP20140881T1/hr unknown
- 2010-06-28 US US13/381,234 patent/US8420632B2/en not_active Expired - Fee Related
- 2010-06-28 KR KR1020147018016A patent/KR20140095108A/ko not_active Abandoned
- 2010-06-28 EP EP10745348.2A patent/EP2448920B1/fr active Active
- 2010-06-28 PT PT107453482T patent/PT2448920E/pt unknown
- 2010-06-28 DK DK10745348.2T patent/DK2448920T3/da active
- 2010-06-28 PL PL10745348T patent/PL2448920T3/pl unknown
-
2013
- 2013-02-22 US US13/774,023 patent/US8633196B2/en not_active Expired - Fee Related
- 2013-12-11 US US14/103,470 patent/US8980897B2/en not_active Expired - Fee Related
-
2014
- 2014-07-08 RU RU2014127843A patent/RU2014127843A/ru not_active Application Discontinuation
- 2014-08-25 JP JP2014170214A patent/JP2014224152A/ja active Pending
- 2014-10-03 CY CY20141100801T patent/CY1115734T1/el unknown
- 2014-11-07 SM SM201400168T patent/SMT201400168B/xx unknown
-
2015
- 2015-02-19 US US14/626,302 patent/US9365529B2/en not_active Expired - Fee Related
- 2015-05-11 HK HK15104437.6A patent/HK1206006A1/xx unknown
-
2016
- 2016-06-03 US US15/173,173 patent/US20160280650A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012531460A5 (enExample) | ||
| RU2014127843A (ru) | Новые бензолсульфонамидные соединения, способ их получения и применение в терапии и косметике | |
| US9029421B2 (en) | Process for the synthesis of arformoterol | |
| JP2012515209A5 (enExample) | ||
| JP2012515724A5 (enExample) | ||
| JP6595078B2 (ja) | アミノカルボニルカルバメート化合物 | |
| HRP20211002T1 (hr) | 1,3-tiazol-2-il supstituirani benzamidi | |
| HRP20140756T1 (hr) | Priprema i terapeutske primjene (2s,3r)-n-2-((3-piridinil)metil)-1-azabiciklo[2.2.2]okt-3-il)-3,5-difluorbenzamida | |
| JP2016529315A5 (enExample) | ||
| NZ601088A (en) | Alpha 4 beta 2 neuronal nicotinic acetylcholine receptor ligands | |
| US20230218562A1 (en) | Aminocarbonylcarbamate compounds | |
| TWI725098B (zh) | 藉由使用極性非質子性溶劑掌性解析n-[4-(1-胺基乙基)-苯基]-磺醯胺衍生物之方法 | |
| JP2018506503A (ja) | Ｎ−［４−（１−アミノエチル）−フェニル］−スルホンアミド誘導体のキラル分割方法 | |
| JP5984988B2 (ja) | （＋）および（−）−１−（３，４−ジクロロフェニル）−３−アザビシクロ［３．１．０］ヘキサンの合成のための方法 | |
| RU2013105479A (ru) | Кристаллическая форма соединения 3-феноксиметилпирролидина | |
| JP2013532170A5 (enExample) | ||
| CN106414376A (zh) | 获得光学活性吡吲哚对映异构体及其盐的方法 | |
| CN1692105A (zh) | 西替利嗪二盐酸盐多晶型物及其制备方法 | |
| JP6947819B2 (ja) | （ｒ）−ｎ−［４−（１−アミノ−エチル）−２，６−ジフルオロ−フェニル］−メタンスルホンアミドの製造方法 | |
| JP6751200B2 (ja) | １−［２−（ジメチルアミノ）−１−（４−ヒドロキシフェニル）エチル］−シクロヘキサノール及びその塩の製造方法 | |
| TW201910313A (zh) | 反式異構雜環化合物及其製備方法 | |
| MX2025011371A (es) | (s)-tianeptina y uso en tratamiento de trastornos y afecciones asociadas con el receptor activado por proliferador de peroxisoma | |
| NZ744194B2 (en) | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar | |
| MX2008008807A (en) | Cycloalkylamines as monoamine reuptake inhibitors | |
| JPWO2023019090A5 (enExample) |